Skip to main content

Table 2 Subgroup analysis based on medication type

From: The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis

Indicator Vasopressin Vasopressin’s analogues
ICU length of stay (MD) − 0.17 (95% CI − 0.98–0.63, P = 0.67, I2 = 0%) 0.03 (95% CI − 0.87–0.93, P = 0.94, I2 = 24%)
Duration of MV (MD) − 1.00 (95% CI −2.39-0.39, P = 0.16)* − 0.50 (95% CI − 1.57–0.57, P = 0.36, I2 = 63%)
Total adverse events (RR) 1.13 (95% CI 0.83–1.53, P = 0.43, I2 = 0%) 1.20 (95% CI 0.52–2.74, P = 0.67, I2 = 79%)
Digital ischemia (RR) 3.33 (95% CI 1.39–7.95, P < 0.001, I2 = 0%) 6.06 (95% CI 2.97–12.37, P < 0.001, I2 = 68%)
Cardiovascular events (RR) 0.93 (95% CI 0.51–1.69, P = 0.80, I2 = 27%) 0.84 (95% CI 0.24–2.99, P = 0.79, I2 = 0%)
Arrhythmia (RR) 0.99 (95% CI 0.51–1.91, P = 0.98, I2 = 15%) 0.57 (95% CI 0.29–1.15, P = 0.12, I2 = 35%)
Mesenteric ischemia (RR) 0.77 (95% CI 0.38–1.53, P = 0.45, I2 = 0%) 1.22 (95% CI 0.26–5.64, P = 0.80, I2 = 42%)
Diarrhea (RR) 0.98 (95% CI 0.06–15.58)* 1.64 (95% CI 0.05–54.19, P = 0.78, I2 = 71%)
Cerebrovascular events (RR) 0.98 (95% CI 0.06–15.58, P = 0.99)* 2.00 (95% CI 0.09–46.68, P = 0.67)*
Hyponatremia (RR) 2.31 (95% CI 0.35–15.09, P = 0.38, I2 = 0%) 1.39 (95% CI 0.78–2.49, P = 0.26)*
  1. RR relative risk, MD mean difference, CI confidence interval, ICU intensive care unit, MV mechanical ventilation
  2. *Only one study